Article · Volume 15, Issue 4 · pp. 767–769

The Cardiotoxic Effects of Remdesivir Administered to the Patients with SARS-CoV Infection Dharti Bhagat1 , Sefali Patel1 , Manoj Dikkatwar2 , Radhika Bindu1

Dharti Bhagat¹, Sefali Patel¹, Manoj Dikkatwar², Radhika Bindu¹

¹Department of Pharmacy Practice, Parul University, Vadodara, Gujarat, INDIA.
²Department of Pharmacy Practice, DY Patil University School of Pharmacy, Affiliated to DY Patil (Deemed to be University), Nerul, Navi Mumbai, Maharashtra, INDIA.

Abstract

Coronavirus has become a pandemic without a reliable treatment since December 2019. The antiviral medication remdesivir, which also inhibits one of the most powerful viral RNA enzymes, RNA dependent RNA polymerase, prevents the SARS-CoV virus from reproducing. Cardiomyocytes can experience substantial cytotoxic effects from remdesivir. Remdesivir binds to human mitochondrial RNA polymerase, which causes cardiotoxicity. A prolonged QT interval and the emergence of torsade de pointes could result from lengthening the field potential duration while lowering the amplitude of the Na+ peak and the pace of spontaneous beating in a dose-dependent way. The current safety profile of Remdesivir is not yet completely established, and it is necessary to evaluate the safety profile and any potential adverse cardiovascular consequences by conducting additional clinical trials. In this case report, adverse effects of remdesivir to assess its safety profile in Covid-19 patients is reviewed.

Keywords: SARS-CoV; Remdesivir; Adverse effect; QT prolongation; Cardiotoxicity; Bradycardia

The full text of this article is available as a PDF. Open the PDF.